Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514062 | 0.87 | GRM2 (0.53) | GRM2LMNAMPOPOLBDPP4 | |
| 7-Chlorokynurenic Acid SCHEMBL157187 | 0.85 | IGFBP3 (0.47) | KMT2APOLBKMO | |
| 7-Chlorokynurenic Acid SCHEMBL31238955 | 0.85 | IGFBP3 (0.47) | KMT2APOLBKMO | |
| 7-Chlorokynurenic Acid SCHEMBL29386783 | 0.85 | IGFBP3 (0.47) | KMT2APOLBKMO | |
| SCHEMBL12349843 | 0.84 | KMT2A (0.52) | GRM2LMNAKMT2AMPONR4A2 | |
| 7-Chlorokynurenic Acid SCHEMBL20770380 | 0.84 | IGFBP3 (0.46) | KMT2APOLBKMO | |
| SCHEMBL1147961 | 0.84 | NR4A2 (0.57) | GRM2LMNAKMT2AMPONR4A2 | |
| SCHEMBL16832238 | 0.81 | GRM2 (0.51) | GRM2LMNAKMT2ANQO2POLB | |
| SCHEMBL9398497 | 0.81 | NQO2 (0.47) | GRM2LMNANQO2 | |
| SCHEMBL9398470 | 0.81 | GRM2 (0.50) | GRM2LMNAMPONQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G | 2007-05-17 | — | — | US | disclosed |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | GRM2 4510/4885LMNA 1818/4885KMT2A 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.